How Can Cancer Cachexia Be Treated? Molecular Subtypes May Be Key
Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.
Muscle RNome Analysis Reveals 2 Molecular Subtypes Associated With Cancer Cachexia
Vickie Baracos, PhD, determined 2 highly coherent molecular subtypes in human muscle from patients with cancer at risk of cachexia.
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS in relapsed/refractory LBCL.
Short-Course Radiation May Be Feasible in Older Rectal Cancer Population
A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
Among patients with locally advanced/metastatic urothelial cancer who received at least one 2.2 mg/kg dose of BL-B01D1, the confirmed ORR was 44.1%.
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
Definitive concurrent chemoradiation followed by consolidation durvalumab in the absence of progression remains the standard of care for stage III NSCLC.
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
Combinations of anti-angiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.
Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers
A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.
Outcomes of haploidentical vs. mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis
Researchers have determined that donor age has a stronger, nonlinear impact on OS vs donor type in allogeneic HCT using posttransplant cyclophosphamide for GVHD prophylaxis, with donor type becoming increasingly relevant in older donors.
Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
Researchers have determined that matched allogeneic donor CD19 CAR T-cell therapy, delivered as a CAR-modified donor lymphocyte infusion, is safe and clinically active for adults with relapsed B-ALL following allogeneic transplant.
HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups
Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.
3 Things You Should Know About Frontline TROP2-Targeting Antibody-Drug Conjugate/Immune Checkpoint Inhibitor Combinations to Treat Advanced Triple-Negative Breast Cancer
Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.
FDA Grants Iopofosine I 131 Rare Pediatric Drug Designation in R/R Glioma
Interim data from the phase 1b CLOVER-2 trial evaluating iopofosine I 131 in children and adults with high-grade glioma supported the FDA’s decision.
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
The Nuclear Medicine Clarification Act seeks to increase transparency in reporting potentially high-dose extravasations in administering radiation.
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
The PSA response rate and radiographic PFS were similar with the 177Lu-based combination regimen vs the radiotracer alone in metastatic CRPC.
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
The safety profile of lenvatinib/pembrolizumab plus TACE among patients with unresectable HCC was consistent with previously reported studies.
Career Stage and Location Found to Impact Oncology Coverage in the US
Rural populations and those with higher cancer burden and socioeconomic risk were found to have gaps in oncology care across the US.
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
Pelareorep Combo Yields Responses in Squamous Cell Anal Carcinoma
Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.
What Is the Impact of the SHARON Trial on Pancreatic Cancer Research?
Kenneth H. Yu, MD, discusses the results from the SHARON trial in pancreatic cancer that were presented at ESMO 2025.
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
Pembrolizumab plus belzutifan is the first combination therapy to improve DFS vs pembrolizumab monotherapy in the adjuvant treatment of those with RCC.
